Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. YD Bio's selling, general, & admin. expense for the
six
months ended in Dec. 2025 was $3.82 Mil.
YD Bio does not have enough years/quarters to calculate its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2025.
YD Bio (NAS:YDES) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
YD Bio Selling, General, & Admin. Expense Related Terms
YD Bio Selling, General, & Admin. Expense Historical Data
* Premium members only.
The historical data trend for YD Bio's Selling, General, & Admin. Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
YD Bio Selling, General, & Admin. Expense Chart
YD Bio Annual Data
Trend
Dec23
Dec24
Dec25
Selling, General, & Admin. Expense
0.16
1.12
3.82
YD Bio Semi-Annual Data
Dec24
Jun25
Dec25
Selling, General, & Admin. Expense
0.00
0.00
3.82
YDES vs ALEC, CAMP, NKTX: Selling, General, & Admin. Expense Comparison
For the Biotechnology subindustry, YD Bio's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
YD Bio Selling, General, & Admin. Expense vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, YD Bio's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where YD Bio's Selling, General, & Admin. Expense falls into.
YD Bio Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
What does a Selling, General, & Admin. Expense of $ Mil mean?
YD Bio (YDES) has a Selling, General, & Admin. Expense of $ Mil as of Dec. 2025. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on YD Bio and its competitors.
Is YD Bio's Selling, General, & Admin. Expense too high?
YD Bio's current Selling, General, & Admin. Expense is $ Mil. Overall, YD Bio has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does YD Bio's Selling, General, & Admin. Expense compare to ALEC and CAMP?
YD Bio's Selling, General, & Admin. Expense of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on YD Bio and its competitors. YD Bio's current Selling, General, & Admin. Expense is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is YD Bio stock overvalued right now?
YD Bio (YDES) has a current Selling, General, & Admin. Expense of $ Mil. The current Selling, General, & Admin. Expense is $ Mil. YD Bio's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For YD Bio (YDES), the current Selling, General, & Admin. Expense is $ Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.
12GF Score
Get the complete analysis for YDES
Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
YDES has been successfully added to your 
